Your browser doesn't support javascript.
loading
Intravenous 5-fluoro-2'-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors.
Coyne, Geraldine O 'Sullivan; Wang, Lihua; Zlott, Jennifer; Juwara, Lamin; Covey, Joseph M; Beumer, Jan H; Cristea, Mihaela C; Newman, Edward M; Koehler, Stephen; Nieva, Jorge J; Garcia, Agustin A; Gandara, David R; Miller, Brandon; Khin, Sonny; Miller, Sarah B; Steinberg, Seth M; Rubinstein, Larry; Parchment, Ralph E; Kinders, Robert J; Piekarz, Richard L; Kummar, Shivaani; Chen, Alice P; Doroshow, James H.
Afiliação
  • Coyne GO'; Division of Cancer Treatment and Diagnosis, National Cancer Institute, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, MD, 20892, USA.
  • Wang L; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Zlott J; Division of Cancer Treatment and Diagnosis, National Cancer Institute, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, MD, 20892, USA.
  • Juwara L; Clinical Monitoring Research Program, Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Covey JM; Division of Cancer Treatment and Diagnosis, National Cancer Institute, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, MD, 20892, USA.
  • Beumer JH; Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA.
  • Cristea MC; Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA.
  • Newman EM; Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA.
  • Koehler S; City of Hope Medical Group, South Pasadena, CA, USA.
  • Nieva JJ; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
  • Garcia AA; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
  • Gandara DR; Louisiana State University, New Orleans, LA, 70112, USA.
  • Miller B; University of California Davis Cancer Center, Sacramento, CA, USA.
  • Khin S; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Miller SB; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Steinberg SM; Division of Cancer Treatment and Diagnosis, National Cancer Institute, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, MD, 20892, USA.
  • Rubinstein L; Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Parchment RE; Division of Cancer Treatment and Diagnosis, National Cancer Institute, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, MD, 20892, USA.
  • Kinders RJ; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Piekarz RL; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Kummar S; Division of Cancer Treatment and Diagnosis, National Cancer Institute, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, MD, 20892, USA.
  • Chen AP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, MD, 20892, USA.
  • Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, 31 Center Drive, Bldg. 31 Room 3A-44, Bethesda, MD, 20892, USA.
Cancer Chemother Pharmacol ; 85(5): 979-993, 2020 05.
Article em En | MEDLINE | ID: mdl-32314030

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células de Transição / Neoplasias Urológicas / Inibidor p16 de Quinase Dependente de Ciclina / Desoxicitidina / DNA (Citosina-5-)-Metiltransferase 1 / Células Neoplásicas Circulantes Tipo de estudo: Clinical_trials Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Chemother Pharmacol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células de Transição / Neoplasias Urológicas / Inibidor p16 de Quinase Dependente de Ciclina / Desoxicitidina / DNA (Citosina-5-)-Metiltransferase 1 / Células Neoplásicas Circulantes Tipo de estudo: Clinical_trials Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Chemother Pharmacol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Alemanha